Biochemist Svetlana Mojsov, honored for GLP-1 research that has transformed metabolic disease care, says she’s grateful to ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased ...

Overall venture funding, as well as “first financing” rounds, fell significantly in the second quarter, reversing 2025’s fast ...

Caribou Biosciences' allogeneic CAR T-cell therapies show promising early efficacy and safety, but require clinical ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

DelveInsight's“ Obesity Pipeline Insigh t 2025 ” report provides comprehensive insights about 80+ companies and 100+ pipeline ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

The National Cancer Center Research Institute in Tokyo reports that a newly isolated gut bacterium, designated ...

DelveInsight’s, “Metastatic Urothelial Carcinoma Pipeline Insight, 2025” report provides comprehensive insights about 40+ ...

In a recent regulatory development, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs ...

MILAN, Italy I July 15, 2025 I AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited ...

In this population-based cohort study, patients with type 2 diabetes who received glucagon-like peptide-1 receptor agonists had a higher risk of developing gastroesophageal reflux disease and ...